A Phase III clinical trial finds that patients with advanced, previously treated melanoma who received the monoclonal antibody ipilimumab lived 34% longer than those who received the gp100 peptide vaccine. The trial is the first randomized study to show an improvement in survival in advanced melanoma, where few treatment options exist and compared efficacy and safety of ipilimumab or gp100 monotherapy and combination. The data was presented during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held from June 4 – 8 in Chicago, IIllinois (USA).

?Over the last 30 years, randomized clinical trials have repeatedly failed to demonstrate an improvement in overall survival in patients with advanced melanoma. It?s an extremely difficult disease to treat,? said lead researcher Steven O?Day, MD, chief of research and director of the melanoma program at The Angeles Clinic and Research Institute in Los Angeles, and clinical associate professor of medicine at the University of Southern California Keck School of Medicine. ?These results are an exciting advance, both for patients with advanced melanoma and for the field of cancer immunology.?


Ipilimumab is a fully human monoclonal antibody against cytotoxic T-lymphocyte antigen-4 that is administered intravenously. Unlike most treatments that target the cancer cell itself, ipilimumab represents a new class of drugs that activate the immune system?s T-cells, which then seek and destroy melanoma cells. Melanoma is one of the most deadly forms of cancer, and over the past three decades, melanoma incidence has climbed faster than any other cancer type.

Study design

Advertisement #3

In the study ? which involved 125 centers internationally ? Dr. O?Day and his colleagues compared the safety and effectiveness of ipilimumab plus placebo (137 patients), ipilimumab plus the gp100 vaccine, and the gp100 vaccine plus placebo (136) in patients with advanced (stage III/IV) melanoma. The gp100 vaccine, an experimental melanoma peptide vaccine also designed to stimulate T cells to attack melanoma cells, was used as a comparison group after previous studies showed it has modest anticancer activity and was superior to IL-2.

Those who received the vaccine alone lived a median of 6.5 months, which is comparable to placebo in past studies. The two arms receiving ipilimumab each lived a median of 10 months. Two-year survival was 24% among the patients who received ipilimumab and 22% among those who received combination treatment, versus 14% for patients who received the gp100 vaccine alone. The team also found better disease control with ipilimumab: after six months, the melanoma did not progress in nearly 30% of those receiving ipilimumab, compared to 11% with the vaccine alone.

Side effects of treatment
Ipilimumab was generally well tolerated; however, between 10% and 14% of ipilimumab patients experienced sometimes severe side effects, such as rash and colitis (inflammation of the colon), compared to about 3% of the vaccine patients.

Plenary Session
Lead Author: Steven O?Day, MD, The Angeles Clinic and Research Institute, Santa Monica, CA,
Date: Sunday, June 6, 2010, 3:05-3:20 PM CDT
Location:N Hall B1.
Abstract: 4
Title: A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.
Authors: S. O’Day, F. S. Hodi, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, X. Zhu, M. J. Yellin, A. Hoos, W. J. Urba

Advertisement #5